The Cost-Effectiveness of Nivolumab for The Treatment of People with Relapsed or Refractory Classical Hodgkin Lymphoma Following Autologous Stem Cell Transplant and Brentuximab Vedotin
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.203
https://www.valueinhealthjournal.com/article/S1098-3015(17)30537-5/fulltext
Title :
The Cost-Effectiveness of Nivolumab for The Treatment of People with Relapsed or Refractory Classical Hodgkin Lymphoma Following Autologous Stem Cell Transplant and Brentuximab Vedotin
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30537-5&doi=10.1016/j.jval.2017.08.203
First page :
A433
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
183